Piotr Tylicki
Overview
Explore the profile of Piotr Tylicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kitlinski M, Heleniak Z, Och A, Tylicki P, Fercho J, Liberek T, et al.
G Ital Nefrol
. 2024 Nov;
41(5.
PMID: 39508709
Patients with nephrotic syndrome (NS) have an increased risk of developing acute ischemic stroke (aIS) and intracranial hemorrhage (ICH). However, the informations on the risk factors for these outcomes are...
2.
Piotrowska M, Zielinski M, Tylicki L, Biedunkiewicz B, Kubanek A, Slizien Z, et al.
Front Immunol
. 2022 Aug;
13:832924.
PMID: 35935974
Clinical Trial Registration Number: www.ClinicalTrials.gov, identifier: NCT04 905 862.
3.
Tylicki P, Polewska K, Och A, Susmarska A, Puchalska-Reglinska E, Parczewska A, et al.
Viruses
. 2022 Mar;
14(3).
PMID: 35336859
The group most at risk of death due to COVID-19 are patients on maintenance hemodialysis (HD). The study aims to describe the clinical course of the early phase of SARS-CoV-2...
4.
Biedunkiewicz B, Tylicki L, Slizien W, Lichodziejewska-Niemierko M, Dabrowska M, Kubanek A, et al.
Vaccines (Basel)
. 2022 Mar;
10(3).
PMID: 35335065
The aim of this study was to analyze the waning of anti-spike (S) antibodies after mRNA vaccination against COVID-19 in maintenance dialysis patients, and to assess the safety and effectiveness...
5.
Tylicki L, Puchalska-Reglinska E, Tylicki P, Och A, Polewska K, Biedunkiewicz B, et al.
J Clin Med
. 2022 Jan;
11(2).
PMID: 35053983
Introduction: The determinants of COVID-19 mortality are well-characterized in the general population. Less numerous and inconsistent data are among the maintenance hemodialysis (HD) patients, who are the population most at...
6.
Och A, Tylicki P, Polewska K, Puchalska-Reglinska E, Parczewska A, Szabat K, et al.
J Clin Med
. 2021 Oct;
10(19).
PMID: 34640471
Background: After recovery from COVID-19, patients frequently face so-called "Post-COVID-19 Syndrome" defined by clusters of persistent symptoms lasting for >12 weeks which may arise from any system in the body....
7.
Tylicki L, Piotrowska M, Biedunkiewicz B, Zielinski M, Dabrowska M, Tylicki P, et al.
Pol Arch Intern Med
. 2021 Oct;
131(10).
PMID: 34632754
No abstract available.
8.
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
Polewska K, Tylicki P, Biedunkiewicz B, Rucinska A, Szydlowska A, Kubanek A, et al.
Medicina (Kaunas)
. 2021 Aug;
57(7).
PMID: 34357013
: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient...
9.
Tylicki L, Biedunkiewicz B, Dabrowska M, Slizien W, Tylicki P, Polewska K, et al.
Pol Arch Intern Med
. 2021 Aug;
131(9):797-801.
PMID: 34351091
Introduction: There is an urgent need to check the efficacy of SARS-CoV-2 vaccination among hemodialysis patients who are known to have large abnormalities of acquired immunity and a catastrophic risk...
10.
Puchalska-Reglinska E, Debska-Slizien A, Biedunkiewicz B, Tylicki P, Polewska K, Jagodzinski P, et al.
Pol Arch Intern Med
. 2021 Jun;
131(7-8):643-648.
PMID: 34105917
Introduction: Preliminary reports suggested high incidence and mortality rates of SARS‑ CoV 2 infection in patients receiving kidney replacement therapy. Objectives: We aimed to describe the incidence and outcomes of...